Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Stoke Therapeutics Inc
0GTCurrent price
11.9 EUR
+0.1 EUR (+0.85%)
Last closed
13.25 USD
Company
www.stoketherapeutics.com
ISIN
US86150R1077
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
677 050 688 USD
Yield for 12 month
+187.85 %
1Y
3Y
5Y
10Y
15Y
0GT
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
23.5 USDP/E ratio
–Dividend Yield
–Current Year
+8 780 000 USD
Last Year
+12 405 000 USD
Current Quarter
+4 831 000 USD
Last Quarter
+4 216 000 USD
Current Year
+4 051 000 USD
Last Year
+12 405 000 USD
Current Quarter
+3 721 000 USD
Last Quarter
+3 103 000 USD
Key Figures 0GT
1 year
3 years
5 years
10 years
EBITDA
-112 162 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-25.35 %
PEG Ratio
–
Return On Equity TTM
-47.85 %
Wall Street Target Price
23.5 USD
Revenue TTM
15 157 000 USD
Book Value
4.64 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-18.2 %
Dividend Yield
–
Gross Profit TTM
12 405 000 USD
Earnings per share
-2.17 USD
Diluted Eps TTM
-2.17 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 0GT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0GT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:9
Payout Ratio
–
Last Split Date
06.06.2019
Dividend Date
–
Stock Valuation 0GT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
26.2153
Price Sales TTM
44.6692
Enterprise Value EBITDA
-3.618
Price Book MRQ
2.7896
Financials 0GT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0GT
For 52 weeks
3.77 USD
17.58 USD
50 Day MA
13.27 USD
Shares Short Prior Month
6 982 876
200 Day MA
11.8 USD
Short Ratio
8.63
Shares Short
6 786 785
Short Percent
19.3 %
BeatStart